Meeting
2023 ASCO Genitourinary Cancers Symposium
Associations of TACSTD2/TROP2 and NECTIN-4/NECTIN-4 with molecular subtypes, PD-L1 expression and FGFR3 mutational status in two advanced urothelial bladder cancer cohorts.
Authors
Veronika Bahlinger
Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany
Veronika Bahlinger , Annalena Branz , Pamela Strissel , Reiner Strick , Fabienne Lange , Carol-Immanuel Geppert , Niklas Klümper , Michael Hölzel , Sven Wach , Helge Taubert , Danijel Sikic , Bernd Wullich , Miriam Angeloni , Fulvia Ferrazzi , Lauri Diehl , Maria Kovalenko , Emon Elboudwarej , Juliane Margarete Juergensmeier , Arndt Hartmann , Markus Eckstein
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Prostate Cancer and Urothelial Carcinoma
Track
Urothelial Carcinoma,Prostate Cancer - Advanced
Sub Track
Translational Research, Tumor Biology, Biomarkers, and Pathology
Citation
J Clin Oncol 41, 2023 (suppl 6; abstr 554)
DOI
10.1200/JCO.2023.41.6_suppl.554
Abstract #
554
Poster Bd #
M17
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
Impact of homologous recombination repair (HRR) or nucleotide excision repair (NER) deficiency on sensitivity to antibody drug conjugate (ADC) payloads in urothelial cancer.
First Author: Surish P Shanmugam
Poster
2024 ASCO Genitourinary Cancers Symposium
Mechanisms and strategies to overcome resistance to enfortumab vedotin in bladder cancer.
First Author: Kevin Chang
Poster
2023 ASCO Annual Meeting
CDH1-mutated clinically advanced urothelial bladder cancer (UBC): A genomic landscape and real-world clinical outcome study (RWCOS).
First Author: Kyle M Rose
Poster
2023 ASCO Genitourinary Cancers Symposium
Biomarkers of response to enfortumab vedotin (EV) in patients (pts) with advanced urothelial carcinoma (aUC): Analysis of the UNITE study.
First Author: Tanya Jindal